| Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy | Frank Vinluan | 01/31/20 | San Francisco |
| Incyte Commits $900M to MorphoSys for Rights to Lymphoma Drug | Frank Vinluan | 01/13/20 | National |
| Merck Ramps Up KRAS Chase Through Licensing Deal With Taiho, Astex | Frank Vinluan | 01/06/20 | New York |
| No More Fish or Fruit: Intrexon Turns SynBio Focus to Human Health | Frank Vinluan | 01/02/20 | National |
| Scripps Research, AbbVie Expand Drug Discovery Deal Beyond Cancer | Sarah de Crescenzo | 12/10/19 | San Diego |
| Roche Notches FDA Nod in Lung Cancer, Amps Up Competition With Merck | Frank Vinluan | 12/04/19 | San Francisco |
| Ferring and Blackstone Team Up to Fund Gene Therapy Firm With $570M | Frank Vinluan | 11/25/19 | Boston |
| ArsenalBio Launches With $85M for “Programmable” T Cell Therapies | Frank Vinluan | 10/17/19 | San Francisco |
| Eli Lilly Drug Acquired in Armo Deal Fails Pancreatic Cancer Test | Frank Vinluan | 10/16/19 | Indiana |
| ESMO 2019: PARP and Prostate, SeaGen’s Win, KRAS Update & More | Ben Fidler | 10/01/19 | National |
| Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More | Frank Vinluan | 09/27/19 | National |
| Gilliland to Step Down as Head of Fred Hutch in 2020 | Jeff Buchanan | 09/17/19 | Seattle |
| FDA Doesn’t Shell Peanut Allergy Drug Pre-Hearing, Aimmune Shares Climb | Frank Vinluan | 09/11/19 | San Francisco |
| Herceptin Inventors, Immunology Pioneers Take Home 2019 Lasker Awards | Ben Fidler | 09/10/19 | National |
| At Big Lung Cancer Meeting, Lights Shine on KRAS, Drug Combos & More | Ben Fidler | 09/09/19 | National |
| Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone | Frank Vinluan | 09/06/19 | National |
| Oncorus Adds $79.5M to Steer Cancer-Fighting Virus to Human Testing | Frank Vinluan | 08/21/19 | Boston |
| Four New Drugs Are Around the Corner. Here’s What You Need to Know. | Ben Fidler | 08/15/19 | National |
| Bio Roundup: Pfizer’s Future, CRISPR in Patients, Drug Imports & More | Frank Vinluan | 08/02/19 | National |
| Merck Data Are Another Step for Immunotherapy in Breast Cancer | Ben Fidler | 07/29/19 | New York |
| Bristol, With Another Lung Cancer Flop, Loses More Ground to Merck | Ben Fidler | 07/24/19 | New York |
| Neon’s Early Vaccine Study Is a Peek at Immunotherapy’s Third Wave | Ben Fidler | 07/15/19 | Boston |
| Bio Roundup: Merger Drama, FDA Trauma, Big IPOs, CRISPR Fights & More | Alex Lash | 06/28/19 | National |
| Mirati Stock Sale Targets $200M as Lead Cancer Drug Starts Phase 3 | Sarah de Crescenzo | 06/26/19 | San Diego |
| Oncolytics Bio Tacks On Cancer Combo Study with Merck KGaA, Pfizer | Sarah de Crescenzo | 06/19/19 | San Diego |
| Bio Roundup: Roche-Spark Drags On, GSK Taps CRISPR, Diabetes News & More | Ben Fidler | 06/14/19 | National |
| Merck Bags Tilos, Adding an Immunotherapy Booster to Its Arsenal | Ben Fidler | 06/10/19 | Boston |
| Bio Roundup: ASCO Wrap, Bluebird’s EU Tap, CRISPR Baby Risk & More | Alex Lash | 06/07/19 | National |
| ASCO 2019: The Long Game, Targeted Pills, First-Ever Buzz & More | Alex Lash | 06/05/19 | National |
| Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer? | Alex Lash | 05/30/19 | National |
